The cost, and that is confidential and was negotiated for all in all , 300 million doses, is slightly lower than the $19.50 per photo the United States agreed to purchase a first shipment of hundred million doses of the identical vaccine, in line with what Reuters reported in November.
The EU file dated Nov. 18 was circulated internally right after the EU announced the supply offer of its with Pfizer and its German partner BioNTech on Nov. 11.
The EU drug regulator is actually expected to determine on Monday on approval for the Pfizer vaccine following the shot was authorised in a number of countries, like Britain and the United States.
On Thursday Belgian state secretary with the budget Eva De Bleeker published on Twitter a dining room table with price tags Belgium will shell out pharmaceutical companies for the COVID 19 vaccines of theirs. She retracted the article shortly after publishing.
In this dinner table the Pfizer vaccine was indicated as costing Belgium twelve euros ($14.6) per dose, leading many to believe this was the full fee agreed with the EU.
Other vaccines in the table were furthermore shown with rates lower compared to rates disclosed by EU solutions.
“There is for sure a complete price and a cost upon delivery,” an EU official required in talks with vaccine creators told Reuters when made to clarify the big difference between the EU and Belgian prices.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality needs, but pointed to what De Bleeker told the Belgian parliament last week. In this public hearing, De Beeker said Belgium’s budgeted prices were still partial.
Under EU advanced purchase deals for COVID-19 vaccines, the bloc concurs initial payments with business enterprises to secure doses before they’re approved. After approvals, EU governments are able to pay the rest to purchase reserved doses.
The EU has not revealed the initial payment agreed with Pfizer.
But, it mentioned in October which it paid aproximatelly one billion euros in downpayments to AstraZeneca, Sanofi and Johnson and Johnson for the shots of theirs, with an additional 1.45 billion euros budgeted for initial payments to Pfizer BioNTech, Moderna and Curevac.
It has since agreed source deals with all six corporations and it is negotiating a seventh understanding with Novavax.